The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling

Molecular and Cellular Biology

Volumn 34, Issue 13, 2014, Pages 2517-2532

  Cen, Bo ^a,b   Xiong, Ying ^a   Song, Jin H ^a,b   Mahajan, Sandeep ^b   DuPont, Rachel ^d   McEachern, Kristen ^d   DeAngelo, Daniel J ^e   Cortes, Jorge E ^f   Minden, Mark D ^g   Ebens, Allen ^h   Mims, Alice ^a   LaRue, Amanda C ^a,b,c   Kraft, Andrew S ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 1208; INITIATION FACTOR 3; INITIATION FACTOR 4B; INITIATION FACTOR 4B S406; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL MOVEMENT; EUKARYOTIC INITIATION FACTOR-3; EUKARYOTIC INITIATION FACTORS; HELA CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS C-PIM-1; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THIAZOLIDINES;

EID: 84901797578     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00147-14     Document Type: Article

References (30)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 2003. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4:915-925. http://dx.doi.org/10.1038/nrm1261.
2. Stoker M, Gherardi E, Perryman M, Gray J. 1987. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327:239-242. http://dx.doi.org/10.1038/327239a0.
3. Mazzone M, Comoglio PM. 2006. The Met pathway: master switch and drug target in cancer progression. FASEB J. 20:1611-1621. http://dx.doi.org/10.1096/fj.06-5947rev.
4. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. 2011. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin. Invest. Drugs 20:1677-1684. http://dx.doi.org/10.1517/13543784.2011.631523.
5. Benvenuti S, Comoglio PM. 2007. The MET receptor tyrosine kinase in invasion and metastasis. J. Cell. Physiol. 213:316-325. http://dx.doi.org/10.1002/jcp.21183.
6. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat. Genet. 16:68-73. http://dx.doi.org/10.1038/ng0597-68.
7. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. 2008. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47: 1025-1037. http://dx.doi.org/10.1002/gcc.20604.
8. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT. 2012. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat. Med. 18:1118-1122. http://dx.doi.org/10.1038/nm.2819.
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. 2007.METamplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043. http://dx.doi.org/10.1126/science.1141478.
10. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS. 2007. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67:2081-2088. http://dx.doi.org/10.1158/0008-5472.CAN-06-3495.
11. Nawijn MC, Alendar A, Berns A. 2011. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer 11:23-34. http://dx.doi.org/10.1038/nrc2986.
12. Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS. 2009. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol. Cancer Ther. 8:1473-1483. http://dx.doi.org/10.1158/1535-7163.MCT-08-1037.
13. Cen B, Mahajan S, Wang W, Kraft AS. 2013. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 73:3402-3411. http://dx.doi.org/10.1158/0008-5472.CAN-12-4619.
14. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. 1996. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin. Cancer Res. 2:1627-1636.
15. Beharry Z, Mahajan S, Zemskova M, Lin YW, Tholanikunnel BG, Xia Z, Smith CD, Kraft AS. 2011. The Pim protein kinases regulate energy metabolism and cell growth. Proc. Natl. Acad. Sci. U. S. A. 108:528-533. http://dx.doi.org/10.1073/pnas.1013214108.
16. Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS. 2010. Regulation of Skp2 levels by the Pim-1 protein kinase. J. Biol. Chem. 285:29128-29137. http://dx.doi.org/10.1074/jbc.M110.137240.
17. van Gorp AG, van der Vos KE, Brenkman AB, Bremer A, van den Broek N, Zwartkruis F, Hershey JW, Burgering BM, Calkhoven CF, Coffer PJ. 2009. AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 28:95-106. http://dx.doi.org/10.1038/onc.2008.367.
18. Merrick WC, Hensold JO. 2001. Analysis of eukaryotic translation in purified and semipurified systems. Curr. Protoc. Cell Biol. Chapter 11: Unit 11.9. http://dx.doi.org/10.1002/0471143030.cb1109s08.
19. Fuss IJ, Kanof ME, Smith PD, Zola H. 2009. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr. Protoc. Immunol. Chapter 7:Unit 7.1. http://dx.doi.org/10.1002/0471142735.im0701s85.
20. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. 2012. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12:89-103. http://dx.doi.org/10.1038/nrc3205.
21. Fram ST, Wells CM, Jones GE. 2011. HGF-induced DU145 cell scatter assay. Methods Mol. Biol. 769:31-40. http://dx.doi.org/10.1007/978-1-61779-207-6_3.
22. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD. 2009. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J. Med. Chem. 52:74-86. http://dx.doi.org/10.1021/jm800937p.
23. Gambarotta G, Pistoi S, Giordano S, Comoglio PM, Santoro C. 1994. Structure and inducible regulation of the human MET promoter. J. Biol. Chem. 269:12852-12857.
24. Zuker M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31:3406-3415. http://dx.doi.org/10.1093/nar/gkg595.
25. Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs BF, Svitkin Y, Sonenberg N. 2010. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol. Cell. Biol. 30:1478-1485. http://dx.doi.org/10.1128/MCB.01218-09.
26. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N. 2006. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 25:2781-2791. http://dx.doi.org/10.1038/sj.emboj.7601166.
27. Cen B, Mahajan S, Wang W, Kraft AS. 2013. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 73:3402-3411. http://dx.doi.org/10.1158/0008-5472.CAN-12-4619.
28. Vornlocher HP, Hanachi P, Ribeiro S, Hershey JW. 1999. A 110-kilodalton subunit of translation initiation factor eIF3 and an associated 135-kilodalton protein are encoded by the Saccharomyces cerevisiae TIF32 and TIF31 genes. J. Biol. Chem. 274:16802-16812. http://dx.doi.org/10.1074/jbc.274.24.16802.
29. Methot N, Song MS, Sonenberg N. 1996. A region rich in aspartic acid, arginine, tyrosine, and glycine (DRYG) mediates eukaryotic initiation factor 4B (eIF4B) self-association and interaction with eIF3. Mol. Cell. Biol. 16:5328-5334.
30. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D. 2009. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114:1618-1627. http://dx.doi.org/10.1182/blood-2008-10-184515.